Trial · NCT00290537
Phase II Study of ZD6474 in Advanced NSCLC
NCT00290537, Phase 2, Terminated, M.D. Anderson Cancer Center; results first posted 2009-06-23
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Phase II Study of ZD6474 in Advanced NSCLC. Trials, record NCT00290537. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00290537
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Phase II Study of ZD6474 in Advanced NSCLC
- NCT number
- NCT00290537
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 4 participants, actual
- Lead sponsor
- M.D. Anderson Cancer Center
- Conditions
- Lung Cancer
- Interventions
- ZD6474, Carboplatin, Paclitaxel
- First posted
- 2006-02-13
- Last updated
- 2016-05-19
- Results first posted
- 2009-06-23
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Response Following Treatment With 300 mg ZD6474 Daily (Study Part One) | Radiologic evaluations performed after weeks 2 and 9 of treatment, then every 2 cycles or as indicated if progressive disease is suspected up to 6 cycles or 18 weeks (1 cycle = 3 weeks). | Evaluate the response rate in patients receiving monotherapy with ZD6474 compared to ZD6474 plus carboplatin plus paclitaxel. No formal comparisons could be made and no conclusions drawn because of small numbers in the treatment groups; a result of an inability to fulfil the recruitment target. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Response Following Treatment With 300 mg ZD6474 Daily (Study Part One) | Radiologic evaluations performed after weeks 2 and 9 of treatment, then every 2 cycles or as indicated if progressive disease is suspected up to 6 cycles or 18 weeks (1 cycle = 3 weeks). | Participants | NUMBER |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Response Following Treatment With 300 mg ZD6474 Daily (Study Part One) | ZD6474 | Complete Response | 1 | Participants | |
| Number of Participants With Response Following Treatment With 300 mg ZD6474 Daily (Study Part One) | ZD6474 | No Change/Stable Disease | 1 | Participants | |
| Number of Participants With Response Following Treatment With 300 mg ZD6474 Daily (Study Part One) | ZD6474 | Progressive Disease | 1 | Participants | |
| Number of Participants With Response Following Treatment With 300 mg ZD6474 Daily (Study Part One) | ZD6474 | Inevaluable for Response | 1 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Part One: ZD6474 | 4 | |
| Overall Study | STARTED | Part Two: ZD6474 + Carboplatin + Paclitaxel | 0 | |
| Overall Study | COMPLETED | Part One: ZD6474 | 4 | |
| Overall Study | COMPLETED | Part Two: ZD6474 + Carboplatin + Paclitaxel | 0 | |
| Overall Study | NOT COMPLETED | Part One: ZD6474 | 0 | |
| Overall Study | NOT COMPLETED | Part Two: ZD6474 + Carboplatin + Paclitaxel | 0 |
Source ClinicalTrials.gov
Adverse events33
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | ALOPECIA | Skin and subcutaneous tissue disorders | ZD6474 | 1 | 4 | 1 |
| other | Alanine aminotransferase increased (ALT, SGPT) | Investigations | ZD6474 | 2 | 4 | 2 |
| other | ANOREXIA | Gastrointestinal disorders | ZD6474 | 1 | 4 | 1 |
| other | Aspartate aminotransferase increased (AST, SGOT) | Investigations | ZD6474 | 2 | 4 | 2 |
| other | DIARRHEA | Gastrointestinal disorders | ZD6474 | 2 | 4 | 2 |
| other | DRY MOUTH | Gastrointestinal disorders | ZD6474 | 1 | 4 | 1 |
| other | DRY SKIN | Skin and subcutaneous tissue disorders | ZD6474 | 2 | 4 | 2 |
| other | DYSPNEA | Respiratory, thoracic and mediastinal disorders | ZD6474 | 1 | 4 | 1 |
| other | EDEMA: LIMB | General disorders | ZD6474 | 1 | 4 | 1 |
| other | ERYTHEMA MULTIFORM | Skin and subcutaneous tissue disorders | ZD6474 | 2 | 4 | 2 |
1 to 10 of 33Source ClinicalTrials.gov
See all 33 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | ZD6474 | ||
| Total, other adverse events | ZD6474 | 4 | 4 |
| Total, serious adverse events | ZD6474 | 0 | 4 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00290537
GET https://conductscience.org/api/trials/v1/NCT00290537/events?page=2